Depth of Sedation and Its Impact on Cerebrovascular Reactivity in Acute Respiratory Distress Syndrome: A Pilot Analysis

Sponsor
University of Manitoba (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05847634
Collaborator
(none)
40
1
19.1
2.1

Study Details

Study Description

Brief Summary

Investigation of the feasibility of monitoring processed transcutaneous electroencephalography (EEG), a method of interpreting brain activity, and near-infrared spectroscopy (NIRS), a method of determining levels of tissue oxygenation (StO2) in the brain, for patients with acute respiratory distress syndrome (ARDS) in the ICU.

Condition or Disease Intervention/Treatment Phase
  • Device: Masimo O3 NIRS cerebral oximetry and SedLine processed EEG

Detailed Description

The aim of this study is to determine the feasibility of using Masimo SedLine processed EEG monitoring and Masimo O3 NIRS to monitor optimal depth of sedation for patients with ARDS in the ICU.

To achieve this, non-invasive devices will be applied to the participant to measure processed EEG signal and StO2. Cerebrovascular reactivity will be determined using the following two values:

  1. SEDopt: The optimal depth of sedation that minimizes correlation between StO2 and processed EEG monitoring.

  2. MAPopt: The optimal blood pressure that minimizes correlation between StO2 and MAP.

Demographic information (age, sex, height, weight), past medical history, etiology of ARDS, Disease severity, routine bloodwork, and dose of sedation will also be documented.

Study Design

Study Type:
Observational
Anticipated Enrollment :
40 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Depth of Sedation and Its Impact on Cerebrovascular Reactivity in Acute Respiratory Distress Syndrome: A Pilot Analysis
Anticipated Study Start Date :
Jul 1, 2023
Anticipated Primary Completion Date :
Feb 1, 2025
Anticipated Study Completion Date :
Feb 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Acute Respiratory Distress Syndrome

Adults admitted to ICU with ARDS confirmed according to Berlin Definition

Device: Masimo O3 NIRS cerebral oximetry and SedLine processed EEG
Non-invasive neuromonitoring device for observational study

Outcome Measures

Primary Outcome Measures

  1. Recruitment [20 months]

    Recruitment of two patients per month, allowing for seasonal variation in ARDS.

  2. Data Quality [7 days]

    Physiologic signal with greater than 80% data quality to allow for calculation of SEDopt

Secondary Outcome Measures

  1. SEDopt [7 days]

    Optimal depth of sedation that minimizes correlation between tissue oxygenation (StO2) and total hemoglobin (THb) as measure by O3 NIRS and processed EEG monitoring as defined by SedLine PSi.

  2. MAPopt [7 days]

    Optimal depth of sedation that minimizes correlation between tissue oxygenation (StO2) and mean arterial pressure as measured by invasive arterial line.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Adult patient admitted to the ICU

  • ARDS confirmed according to the Berlin Definition

  • Invasive mechanical ventilation

  • Deep sedation and/or neuromuscular blockade required for ARDS treatment at the discretion of the treating medical team

  • Application of monitoring devices feasible

Exclusion Criteria:
  • More than 24 hours elapsed since ICU admission

  • Death is deemed imminent and inevitable during the next 24 hours

  • Known allergy to a textile component of the device

  • Consent declined from patient or authorized third party

  • The treating clinician believes that participation in the study would not be in the best interest of the patient

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Manitoba Winnipeg Manitoba Canada R3T2N2

Sponsors and Collaborators

  • University of Manitoba

Investigators

  • Principal Investigator: Asher Mendelson, MD PhD, University of Manitoba

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Asher Mendelson, Assistant Professor, University of Manitoba
ClinicalTrials.gov Identifier:
NCT05847634
Other Study ID Numbers:
  • HS25505
First Posted:
May 6, 2023
Last Update Posted:
May 6, 2023
Last Verified:
Apr 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Asher Mendelson, Assistant Professor, University of Manitoba
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 6, 2023